All In Biotech

Drug Trial Radar · NCT07209813

GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma

A Multicenter, Randomized, Open-Label, Controlled Phase 2 Study of GKL-006 Injection in Combination With Transarterial Chemoembolization (TACE) Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma

Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Nov 14, 2025

Primary completion

Sep 30, 2027

Study completion Oct 31, 2027

Sponsor

Sponsor type
Industry
First posted
Oct 7, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, open-label, controlled Phase 2 study in patients with unresectable hepatocellular carcinoma (uHCC). The purpose of this study is to compare the efficacy and safety of GKL-006 Injection in combination with transarterial chemoembolization (TACE) versus TACE alone.

Conditions

  • Hepatocellular Carcinoma (HCC)
  • Unresectable Hepatocellular Cancer

Interventions

  • GKL-006 InjectionDrug

    An iNKT cell therapy

  • TACEProcedure

    A standard locoregional therapy for hepatocellular carcinoma

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) Assessed by Independent Review Committee Based on mRECISTTime frame: Up to approximately 18 months

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • 302 Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China · Recruiting

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, China · Recruiting

  • Zhongda Hospital

    Nanjing, Jiangsu, China · Recruiting

  • Nanjing Second Hospital

    Nanjing, Jiangsu, China · Recruiting

  • Jiangxi Cancer Hospital

    Nanchang, Jiangxi, China · Recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.